Wiener klinische Wochenschrift

, Volume 121, Issue 13–14, pp 473–482

Stellenwert von Langzeit-Insulin-Analoga in der Therapie des Diabetes mellitus Typ 2

  • Bernhard Ludvik
  • Helmut Brath
  • Thomas Wascher
  • Hermann Toplak
Positionspapier

Zusammenfassung

Etwa 5 bis 10% der europäischen Bevölkerung sind Diabetiker, wobei die Prävalenz – auch in Österreich – stark ansteigt. Die wesentlichen Therapieziele bei Diabetes mellitus sind die Vermeidung von Komplikationen und Organschäden, die Vermeidung schwerer Hypo- und Hyperglykämien und die Erhaltung der Lebensqualität. Viele Typ-2-Diabetiker benötigen im Lauf ihrer Erkrankung früher oder später Insulin, wobei die Verabreichung eines lang wirksamen Insulins bzw. Insulinanalogons die einfachste – und leitlinienkonforme – Art ist, eine Insulinisierung zu beginnen. Die bestehende Datenlage zeigt, dass die Anwendung von lang wirksamen Insulinanaloga bei Patienten mit Typ-2-Diabetes, die mit oralen Antidiabetika unzureichend eingestellt sind, einfach, sicher und effizient ist. Diese Therapieoption sollte dem Arzt und dem Patienten die Entscheidung für den Beginn einer Insulintherapie erleichtern und daher uneingeschränkt zur Verfügung stehen. Das vorliegende Positionspapier fasst die diesbezügliche Datenlage zusammen.

Schlüsselwörter

Diabetes mellitus Typ-2-Diabetes Insulinanaloga Insulin glargin Insulin detemir 

The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus

Summary

Between 5 and 10% of the European population suffers from diabetes, and its prevalence is constantly rising, in Austria like in other countries. The main goals in the treatment of diabetes mellitus are the prevention of complications and organ damage, the prevention of severe hypo- and hyperglycaemia and the preservation of quality of life. Many patients with type 2 diabetes become insulin-dependent in the course of their disease. The application of a long acting insulin or insulin analogue is the simplest way of initiating an insulin therapy and is in accordance with current guidelines. Current scientific evidence shows that the use of long acting insulin analogues for type 2 diabetes; which can no longer be sufficiently controlled with oral antidiabetic agents, is simple, safe and efficacious. Thus, this treatment option should be available without any restrictions to physicians and patients in order to facilitate the beginning of an insulin regime. This position paper summarises up the current evidence concerning this subject.

Keywords

Diabetes mellitus Type 2 diabetes Insulin analogues Insulin glargine Insulin detemir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Keine Autoren angegeben (2007) Diabetes mellitus – guidelines for general practice. Revised and expanded 2007 edition. Wien Klin Wochenschr 119: 5–64Google Scholar
  2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577–1589PubMedCrossRefGoogle Scholar
  3. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359: 1565–1576PubMedCrossRefGoogle Scholar
  4. Rieder A, Rathmanner T, Kiefer I, Dorner T, Kunze M, Schwarz F (2004) Österreichischer Diabetesbericht 2004 – Daten, Fakten, Strategien. Abrufbar von der Homepage der Österreichischen Diabetesgesellschaft, www.oedg.org/diabetesbericht_2004html
  5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383–393PubMedCrossRefGoogle Scholar
  6. Rosenstock J, Park G, Zimmerman J (2000) Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23: 1137–1142PubMedCrossRefGoogle Scholar
  7. Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 23: 157–162PubMedCrossRefGoogle Scholar
  8. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23: 1666–1671PubMedCrossRefGoogle Scholar
  9. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23: 639–643PubMedCrossRefGoogle Scholar
  10. Witthaus E, Stewart J, Bradley C (2001) Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 18: 619–625PubMedCrossRefGoogle Scholar
  11. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K (2002) Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 15: 369–376PubMedGoogle Scholar
  12. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, et al (2003) Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26: 799–804PubMedCrossRefGoogle Scholar
  13. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al (2004) Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21: 1213–1220PubMedCrossRefGoogle Scholar
  14. Fulcher GR, Gilbert RE, Yue DK (2005) Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35: 536–542PubMedCrossRefGoogle Scholar
  15. Thisted H, Johnsen SP, Rungby J (2006) An update on the long-acting insulin analogue glargine. Basic Clin Pharmacol Toxicol 99: 1–11PubMedCrossRefGoogle Scholar
  16. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, et al (2003) Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26: 1490–1496PubMedCrossRefGoogle Scholar
  17. Hershon KS, Blevins TC, Mayo CA, Rosskamp R (2004) Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract 10: 10–17PubMedGoogle Scholar
  18. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A (2005) A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 21: 545–553PubMedCrossRefGoogle Scholar
  19. Clissold R, Clissold S (2007) Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evidence 2: 89–110Google Scholar
  20. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU (2007) Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 29: 1607–1619PubMedCrossRefGoogle Scholar
  21. Gough SC (2007) A review of human and analogue insulin trials. Diabetes Res Clin Pract 77: 1–15PubMedCrossRefGoogle Scholar
  22. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, et al (2005) Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7: 73–82PubMedCrossRefGoogle Scholar
  23. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA (2004) Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47: 622–629PubMedCrossRefGoogle Scholar
  24. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24: 296–301PubMedCrossRefGoogle Scholar
  25. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al (2004) Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27: 1081–1087PubMedCrossRefGoogle Scholar
  26. Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, et al (2006) Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 23: 729–735PubMedCrossRefGoogle Scholar
  27. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J (2007) Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 24: 27–34PubMedCrossRefGoogle Scholar
  28. Standl E, Lang H, Roberts A (2004) The 12-month efficacy and safety of insulin detemir and NPH insulin in basalbolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther 6: 579–588PubMedCrossRefGoogle Scholar
  29. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, et al (2003) Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26: 590–596PubMedCrossRefGoogle Scholar
  30. Pieber TR, Draeger E, Kristensen A, Grill V (2005) Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 22: 850–857PubMedCrossRefGoogle Scholar
  31. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26: 724–736PubMedCrossRefGoogle Scholar
  32. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28: 950–955PubMedCrossRefGoogle Scholar
  33. Fritsche A, Schweitzer MA, Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138: 952–959PubMedGoogle Scholar
  34. Rosenstock J, Schwartz SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24: 631–636PubMedCrossRefGoogle Scholar
  35. Yki-Järvinen H, Dressler A, Ziemen M (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23: 1130–1136PubMedCrossRefGoogle Scholar
  36. (2003) Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 20: 545–551Google Scholar
  37. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, et al (2006) Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 37: 495–501PubMedCrossRefGoogle Scholar
  38. Linn T, Fischer B, Soydan N, Eckhard M, Ehl J, Kunz C, et al (2008) Nocturnal Glucose Metabolism after Bedtime Injection of Insulin Glargine or NPH Insulin in Patients with Type 2 Diabetes. J Clin Endocrinol Metab; e-pub 2008/07/10; doi: 10.1210/jc.2007–2871Google Scholar
  39. Massi Benedetti M, Humburg E, Dressler A, Ziemen M (2003) A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35: 189–196PubMedCrossRefGoogle Scholar
  40. Pan CY, Sinnassamy P, Chung KD, Kim KW (2007) Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 76: 111–118PubMedCrossRefGoogle Scholar
  41. Siegmund T, Weber S, Blankenfeld H, Oeffner A, Schumm-Draeger PM (2007) Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 115: 349–353PubMedCrossRefGoogle Scholar
  42. Wang XL, Lu JM, Pan CY, Mu YM, Dou JT, Ba JM, et al (2007) Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res Clin Pract 76: 30–36PubMedCrossRefGoogle Scholar
  43. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49: 442–451PubMedCrossRefGoogle Scholar
  44. Riddle MC, Rosenstock J, Gerich J (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080–3086PubMedCrossRefGoogle Scholar
  45. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE (2004) A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 328: 274–280PubMedCrossRefGoogle Scholar
  46. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V (2008) Safety and efficacy of glargine compared with NPH insulin for the treatment of Type-2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 25: 924–932PubMedCrossRefGoogle Scholar
  47. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M (2006) Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 73: 35–40PubMedCrossRefGoogle Scholar
  48. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al (2007) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD005613Google Scholar
  49. Monami M, Marchionni N, Mannucci E (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81: 184–189PubMedCrossRefGoogle Scholar
  50. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P (2006) A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29: 1269–1274PubMedCrossRefGoogle Scholar
  51. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B (2006) Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28: 1569–1581PubMedCrossRefGoogle Scholar
  52. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N (2004) Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66: 193–201PubMedCrossRefGoogle Scholar
  53. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W (2005) Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7: 56–64PubMedCrossRefGoogle Scholar
  54. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371: 1073–1084PubMedCrossRefGoogle Scholar
  55. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29: 554–559PubMedCrossRefGoogle Scholar
  56. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28: 1282–1288PubMedCrossRefGoogle Scholar
  57. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R (2008) Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes Metab 10: 387–399PubMedCrossRefGoogle Scholar
  58. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E (2006) A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or sub-maximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 23: 736–742PubMedCrossRefGoogle Scholar
  59. Harris S, Yale JF, Dempsey E, Gerstein H (2008) Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician 54: 550–558PubMedGoogle Scholar
  60. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, et al (2008) Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 45: 53–59PubMedCrossRefGoogle Scholar
  61. Vinik AI, Zhang Q (2007) Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 30: 795–800PubMedCrossRefGoogle Scholar
  62. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC (2007) Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 78: 254–258PubMedCrossRefGoogle Scholar
  63. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357: 1716–1730PubMedCrossRefGoogle Scholar
  64. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559PubMedCrossRefGoogle Scholar
  65. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129–139PubMedCrossRefGoogle Scholar
  66. Davies M, Khunti K (2008) Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes Obes Metab 10 Suppl 2: 42–49CrossRefGoogle Scholar
  67. Kosiborod M, Quanwu Z, Foody J (2007) Association between therapy with insulin glargine versus NPH and the risk of myocardial infarction in patients with Type 2 diabetes. Circulation 116: AHA-Abstract #3737Google Scholar
  68. Janka HU, Hogy B (2008) Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 9: 165–170PubMedCrossRefGoogle Scholar
  69. Lechleitner M, Roden M, Haehling E, Mueller M (2005) Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 117: 593–598PubMedCrossRefGoogle Scholar
  70. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 23: 21–31CrossRefGoogle Scholar
  71. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin 23: 7–19CrossRefGoogle Scholar
  72. McEwan P, Mehin N, Tetlow AP, Sharplin P (2007) The relative cost-effectiveness of insulin glargine vs NPH insulin using UK real-life data in patients with type 2 diabetes mellitus. ISPOR 10th Annual European CongressGoogle Scholar
  73. McEwan P, Mehin N, Tetlow AP, Sharplin P (2007) The relative cost-effectiveness of insulin glargine vs NPH insulin using UK real-life data in patients with type 1 diabetes mellitus and the combined effect of HbA1C and hypoglycaemia reduction. ISPOR 10th Annual European CongressGoogle Scholar
  74. Dailey G (2008) Optimum management of type 2 diabetes – timely introduction, optimization and intensification of basal insulin. Diabetes Obes Metab 10: 5–13PubMedCrossRefGoogle Scholar
  75. Bradley C, Gilbride CJB (2008) Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes Metab 10: 50–65PubMedCrossRefGoogle Scholar
  76. Hemkens LG, Grouven U, Bender R, et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia published online June 30. DOI:10.1007/s00125-009-1418-4Google Scholar
  77. SDRN Epidemiology Group. (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group http://webcast.easd.org/press/glargine/download/090818Colhounacceptedpaperadjusted.pdf (accessed July 10, 2009)
  78. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. (2009) Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia published online. DOI:10.1007/s00125-009-1444-2Google Scholar
  79. Currie CJ, Poole CD, Gale EA. (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia published online July 2. DOI:10.1007/s00125-009-1440-6Google Scholar
  80. Rosenstock J, Fonseca V, McGill JB, et al. (2009) Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: fi ndings from a 5 year randomised, open-label study. Diabetologia published online. DOI:10.1007/s00125-009-1452-2Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Bernhard Ludvik
    • 1
  • Helmut Brath
    • 2
  • Thomas Wascher
    • 3
  • Hermann Toplak
    • 4
  1. 1.Universitätsklinik für Innere Medizin IIIMedizinische Universität WienAustria
  2. 2.DiabetesambulanzGesundheitszentrum SüdWienAustria
  3. 3.1. Medizinische AbteilungHanusch-KrankenhausWienAustria
  4. 4.Universitätsklinik für Innere MedizinMedizinische Universität GrazAustria

Personalised recommendations